| John Michael Barraza, MD | |
|
1888 Hudson Cir, Ste 2, Monroe, LA 71201-3546 | |
| (318) 387-3453 | |
| (318) 323-9045 |
| Full Name | John Michael Barraza |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 42 Years |
| Location | 1888 Hudson Cir, Monroe, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639108012 | NPI | - | NPPES |
| 115102001 | Medicaid | AR | |
| 1366889 | Medicaid | LA | |
| 300134865 | Other | LA | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 016721 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Medical Center | Monroe, LA | Hospital |
| West Carroll Memorial Hospital | Oak grove, LA | Hospital |
| Citizens Medical Center | Columbia, LA | Hospital |
| Our Lady Of The Lake Regional Medical Center | Baton rouge, LA | Hospital |
| Richland Parish Hospital-delhi | Delhi, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopaedic Clinic Of Monroe | 0840252698 | 34 |
| Radiology Associates A Professional Corporation | 4284670092 | 12 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.
› Verified 1 days ago
| Entity Name | Orthopaedic Clinic Of Monroe |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144266511 PECOS PAC ID: 0840252698 Enrollment ID: O20041103000304 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.
› Verified 1 days ago
| Entity Name | Radiology Associates A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104855402 PECOS PAC ID: 4284670092 Enrollment ID: O20050701000504 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Michael Barraza, MD 1888 Hudson Cir, Ste 2, Monroe, LA 71201-3546 Ph: (318) 387-3453 | John Michael Barraza, MD 1888 Hudson Cir, Ste 2, Monroe, LA 71201-3546 Ph: (318) 387-3453 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.
› Verified 1 days ago
Mr. Lovick Pierce Thomas Vi, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1601 Lamy Lane, Monroe, LA 71201 Phone: 318-387-3453 Fax: 318-323-9045 | |
Robert David Halsell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1888 Hudson Cir, Ste 2, Monroe, LA 71201 Phone: 318-387-3453 Fax: 318-323-9045 | |
Jesse Merwin Lapietra, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1888 Hudson Cir, Ste 2, Monroe, LA 71201 Phone: 318-387-3453 Fax: 318-323-9045 | |
Robert Bruce Golson, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1601 Lamy Ln, Monroe, LA 71201 Phone: 318-387-3453 Fax: 318-323-9045 | |
John Allen Davis, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1888 Hudson Cir, Ste 2, Monroe, LA 71201 Phone: 318-387-3453 Fax: 318-323-9045 | |
Mr. Ross Edward Bland, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 411 Calypso Street, Monroe, LA 71201 Phone: 318-966-1900 | |
Brenton Wayne Mcdonald, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2807 Evangeline St, Monroe, LA 71201 Phone: 318-737-2269 Fax: 318-324-1719 |